Therefore, we performed MDA-MB-231 xenografts that were treated with FTY720 in order to both investigate the potential therapeutic value of the CIP2A/AKT signaling as a novel molecular target in breast cancer and validatein vivo the role of CIP2A as a p-AKT regulator. The gene discussed is AKT1; the disease is breast carcinoma.